Altered expression of 12S/MT-RNRI, MT-CO2/COX2, and MT-ATP6 mitochondrial genes in prostate cancer

Prostate

Volumn 68, Issue 10, 2008, Pages 1086-1096

  Abril, Jesús ^a   De Heredia, Miguel López ^a,b   González, Laura ^a,b   Clèries, Ramon ^c   Nadal, Marga ^a   Condom, Enric ^d   Aguiló, Fernando ^d   Gómez Zaera, Montserrat ^a,f   Nunes, Virginia ^a,b,e  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f THOMSON SCIENTIFIC   (United Kingdom)

Author keywords

Gene expression; Mitochondrial RNA transcripts; mtDNA; Prostate cancer; RT qPCR

Indexed keywords

CYCLOPHILIN A;

12S MT RNR1 GENE; 16S MT RNR2 GENE; ACO2 GENE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COX11 GENE; CS GENE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GSR GENE; HUMAN; HUMAN TISSUE; MALE; MITOCHONDRIAL GENE; MT ATP6 GENE; MT CO2 COX2 GENE; MT CYB GENE; MT ND2 GENE; MT ND6 GENE; MTND4 GENE; PPIA GENE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION;

ACONITATE HYDRATASE; AGED; DNA-BINDING PROTEINS; ELECTRON TRANSPORT COMPLEX IV; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MITOCHONDRIAL; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; NADH DEHYDROGENASE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 45749154203     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20771     Document Type: Article

References (63)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361(9360):859-864.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
3. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992;23(3):211-222.
4. Costello LC, Franklin RB. The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000;59(4):269-282.
5. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991;18(1):25-46.
6. Costello LC, Franklin RB. Bioenergetic theory of prostate malignancy. Prostate 1994;25(3):162-166.
7. Costello LC, Franklin RB. Citrate metabolism of normal and malignant prostate epithelial cells. Urology 1997;50(1):3-12.
8. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998;35(4):285-296.
9. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate. Prostate 1991;19(3):181-205.
10. Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005;5(3):143-153.
11. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59(1):10-16.
12. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002;1:9.
13. Penta JS, Johnson FM, Wachsman JT, Copeland WC. Mitochondrial DNA in human malignancy. Mutat Res 2001;488(2):119-133.
14. Wallace DC. A mitochondrial paradigm for degenerative diseases and ageing. Novartis Found Symp 2001;235:247-263; discussion 246-266.
15. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 2005;70:363-374.
16. Warburg O. On the origin of cancer cells. Science 1956;123(3191):309-314.
17. Debatin KM, Poncet D, Kroemer G. Chemotherapy: Targeting the mitochondrial cell death pathway. Oncogene 2002;21(57):8786-8803.
18. Don Anthony SHP. Mitochondria as cancer drug targets. Trends Mol Med 2004;10(8):372-378.
19. Kagan J, Srivastava S. Mitochondria as a target for early detection and diagnosis of cancer. Crit Rev Clin Lab Sci 2005;42(5-6):453-472.
20. Morisaki T, Katano M. Mitochondria-targeting therapeutic strategies for overcoming chemoresistance and progression of cancer. Curr Med Chem 2003;10(23):2517-2521.
21. Gomez-Zaera M, Abril J, Gonzalez L, Aguilo F, Condom E, Nadal M, Nunes V. Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients. Mutat Res 2006;595(1-2):42-51.
22. Jeronimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, Oliveira J, Lopes C, Fliss MS, Sidransky D. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001;20(37):5195-5198.
23. Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res 2002;62(22):6470-6474.
24. Shen XY, Zacal N, Singh G, Rainbow AJ. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells. Photochem Photobiol 2005;81(2):306-313.
25. Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S, Franc B, Rodien P, Rohmer V, Bertucci F, Birnbaum D, Malthiery Y, Reynier P, Houlgatte R. Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab 2004;89(2):994-1005.
26. Dmitrenko V, Shostak K, Boyko O, Khomenko O, Rozumenko V, Malisheva T, Shamayev M, Zozulya Y, Kavsan V. Reduction of the transcription level of the mitochondrial genome in human glioblastoma. Cancer Lett 2005;218(1):99-107.
27. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC. The bioenergetic signature of cancer: A marker of tumor progression. Cancer Res 2002;62(22):6674-6681.
28. Rodriguez-Santiago B, Nunes V. Expression of mitochondrial genes and transcription estimation in different brain areas in Alzheimer's disease patients. Neurobiol Dis 2005;18(2):296-304.
29. Higuchi M, Kudo T, Suzuki S, Evans TT, Sasaki R, Wada Y, Shirakawa T, Sawyer JR, Gotoh A. Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene 2006;25(10):1437-1445.
30. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006;97(3):433-447.
31. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A, Wittock R, Robinson K, Alexander JS, Birch-Machin MA, AbdelMalak M, Froberg MK, Diamandis EP, Thayer RE. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006;8(3):312-319.
32. Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L, Petros JA, Arnold RS. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 2005;62(2):200-207.
33. Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res 2007;13 (2 Pt 1):421-426.
34. Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W, Kim SS. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 2007;67(8):3654-3662.
35. Costello AJ. Contemporary view of prostate cancer diagnosis and treatment. Aust Fam Physician 2003;32(6):396-398.
36. Costello L. Intermediary metabolism of normal and malignant prostate: A neglected area of prostate research. Prostate 1998;34(4):303-304.
37. Costello LC, Liu Y, Zou J, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate 2000;42(3):196-202.
38. Libus J, Storchova H. Quantification of cDNA generated by reverse transcription of total RNA provides a simple alternative tool for quantitative RT-PCR normalization. Biotechniques 2006;41(2):156-160.
39. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PC. Nucleic Acids Res 2001;29(9):e45.
40. Chen Y, Dougherty ER, Bittner ML. Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Opt 1997;2(4):364.
41. Newton MA, Kendziorski CM, Richmond CS, Blattner FR, Tsui KW. On differential variability of expression ratios: Improving statistical inference about gene expression changes from microarray data. J Comput Biol 2001;8(1):37-52.
42. Gelman A, Carlin JB, Stern H, Rubin DB. Bayesian data analysis. London: Chapman & Hall; 2003.
43. Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonic A, Jung K. Gene expression studies in prostate cancer tissue: Which reference gene should be selected for normalization? J Mol Med 2005;83(12):1014-1024.
44. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN. Normalization of gene expression measurements in tumor tissues: Comparison of 13 endogenous control genes. Lab Invest 2005;85(1):154-159.
45. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, Grisar T, Igout A, Heinen E. Housekeeping genes as internal standards: Use and limits. J Biotechnol 1999;75(2-3):291-295.
46. Brothman AR. Cytogenetics and molecular genetics of cancer of the prostate. Am J Med Genet 2002;115(3):150-156.
47. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-2. Cancer Res 1996;56(10):2411-2416.
48. Friedrichsen DM, Stanford JL, Isaacs SD, Janer M, Chang BL, Deutsch K, Gillanders E, Kolb S, Wiley KE, Badzioch MD, Zheng SL, Walsh PC, Jarvik GP, Hood L, Trent JM, Isaacs WB, Ostrander EA, Xu J. Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proc Natl Acad Sci USA 2004;101(7):1939-1944.
49. Gillanders EM, Xu J, Chang BL, Lange EM, Wiklund F, Bailey-Wilson JE, Baffoe-Bonnie A, Jones M, Gildea D, Riedesel E, Albertus J, Isaacs SD, Wiley KE, Mohai CE, Matikainen MP, Tammela TL, Zheng SL, Brown WM, Rokman A, Carpten JD, Meyers DA, Walsh PC, Schleutker J, Gronberg H, Cooney KA, Isaacs WB, Trent JM. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 2004;96(16):1240-1247.
50. Wolf M, Mousses S, Hautaniemi S, Karhu R, Huusko P, Allinen M, Elkahloun A, Monni O, Chen Y, Kallioniemi A, Kallioniemi OP. High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: Impact of copy number on gene expression. Neoplasia 2004;6(3):240-247.
51. Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 1999;39(2):79-86.
52. Crundwell MC, Chughtai S, Knowles M, Takle L, Luscombe M, Neoptolemos JP, Morton DG, Phillips SM. Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer. Int J Cancer 1996;69(4):295-300.
53. Lexander H, Palmberg C, Hellman U, Auer G, Hellstrom M, Franzen B, Jornvall H, Egevad L. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics 2006;6(15):4370-4380.
54. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, Huwendiek S, Linder S, Auer G. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000;21(1):1-9.
55. Alaiya AA, Oppermann M, Langridge J, Roblick U, Egevad L, Brindstedt S, Hellstrom M, Linder S, Bergman T, Jornvall H, Auer G. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci 2001;58(2):307-311.
56. Shen C, Nathan C. Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol Med 2002;8(2):95-102.
57. de Heredia ML, Izquierdo JM, Cuezva JM. A conserved mechanism for controlling the translation of beta-F1-ATPase mRNA between the fetal liver and cancer cells. J Biol Chem 2000;275(10):7430-7437.
58. Piechota J, Tomecki R, Gewartowski K, Szczesny R, Dmochowska A, Kudla M, Dybczynska L, Stepien PP, Bartnik E. Differential stability of mitochondrial mRNA in HeLa cells. Acta Biochim Pol 2006;53(1):157-168.
59. Shadel GS. Coupling the mitochondrial transcription machinery to human disease. Trends Genet 2004;20(10):513-519.
60. Roy D, Felty Q, Narayan S, Jayakar P. Signature of mitochondria of steroidal hormones-dependent normal and cancer cells: Potential molecular targets for cancer therapy. Front Biosci 2007;12:154-173.
61. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF III. Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 2003;3(9):1801-1810.
62. Higuchi M. Regulation of mitochondrial DNA content and cancer. Mitochondrion 2007;7(1-2):53-57.
63. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 2005;102(3):719-724.